Photobiomodulation Therapy Scheduling for Early Dry AMD
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for dry age-related macular degeneration (AMD) are limited, and there is a significant unmet clinical need for effective therapies, particularly for the dry form, which affects a large and growing population.
Innovation Solution
Photobiomodulation (PBM) therapy using red, yellow, and near-infrared light ranges is administered to treat dry AMD, with follow-up treatments given at least 4 to 6 months after initial therapy, targeting subjects with better baseline vision and early-stage disease.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If periodic intravitreal injections of Anti-VEGF compounds are administered, then wet AMD is treated, but the treatment is invasive and requires frequent medical interventions
Solution Approach 1:
The patent replaces the mechanical injection procedure with photobiomodulation therapy using light energy. Instead of physically injecting Anti-VEGF compounds into the vitreous humor, the invention uses non-invasive light delivery through optical devices to stimulate cellular repair mechanisms in the retina, thereby treating AMD without invasive procedures
Solution Approach 2:
The patent introduces light as an intermediary substance that mediates the treatment process. Rather than directly administering pharmaceutical compounds, light energy serves as the intermediary that triggers biochemical pathways in retinal cells, particularly activating cytochrome c oxidase to promote cellular repair and reduce drusen accumulation
2Ease of operation
If lifestyle changes and vitamin supplements are used for dry AMD, then treatment is non-invasive, but the therapeutic effect is limited
Solution Approach 1:
The patent changes the fundamental parameter of treatment from passive nutritional supplementation to active photobiological stimulation. By introducing light energy as a new parameter, the treatment activates specific photoreceptors and mitochondrial pathways that are not stimulated by vitamins alone, thereby enhancing therapeutic effectiveness while maintaining non-invasive accessibility
Solution Approach 2:
The patent implements periodic light therapy sessions that deliver controlled doses of photobiomodulation at regular intervals. This periodic action maintains sustained therapeutic effects by continuously stimulating cellular repair mechanisms without the need for daily oral supplementation, improving both effectiveness and patient compliance
3Reliability
If photobiomodulation therapy is administered, then visual acuity is improved and drusen volume is reduced, but multiple treatment sessions are required
Solution Approach 1:
The patent implements a series of photobiomodulation treatment sessions that maintain continuous therapeutic action over time. Rather than relying on a single treatment, multiple sessions are administered at regular intervals to sustain the activation of cellular repair pathways, ensuring continuous reduction of drusen and improvement of visual function throughout the treatment period
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
PBM therapy improves visual acuity and reduces drusen volume and thickness, enhancing quality of life by stabilizing disease progression and improving daily activities in subjects with dry AMD.
Implementation Method 1
Photobiomodulation (PBM) therapy using red, yellow, and near-infrared light ranges is administered to treat dry AMD
Data Source
AI summary
Methods for treating ocular diseases such as dry age-related macular degeneration include administering non-invasive photobiomodulation light therapy in the context of a prior PBM treatment, on the basis of a subject response to prior PBM treatment, on the basis of a patient pre-treatment characteristic, and combinations thereof. In some embodiments, methods comprise administering PBM therapy to subjects who have received PBM about four to six months prior to the present administering. In some embodiments, methods comprise administering PBM therapy to subjects in early stages of dry age-related macular degeneration.